Tectonic Therapeutic, Inc. (TECX)
Automate Your Wheel Strategy on TECX
With Tiblio's Option Bot, you can configure your own wheel strategy including TECX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TECX
- Rev/Share 0.0
- Book/Share 14.2965
- PB 1.4675
- Debt/Equity 0.0046
- CurrentRatio 29.1519
- ROIC -0.2889
- MktCap 392667554.0
- FreeCF/Share -3.3479
- PFCF -6.2677
- PE -5.8337
- Debt/Assets 0.0045
- DivYield 0
- ROE -0.2711
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TECX | Wells Fargo | -- | Overweight | -- | $101 | Oct. 20, 2025 |
| Initiation | TECX | Oppenheimer | -- | Outperform | -- | $80 | Sept. 3, 2025 |
| Initiation | TECX | Truist | -- | Buy | -- | $64 | July 21, 2025 |
| Resumed | TECX | Raymond James | -- | Outperform | -- | $76 | June 11, 2025 |
| Initiation | TECX | Mizuho | -- | Outperform | -- | $51 | April 21, 2025 |
| Initiation | TECX | Wells Fargo | -- | Overweight | -- | $55 | Aug. 22, 2024 |
News
Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) patients. TECX is targeting CpcPH patients with PVR >3 in the ongoing phase 2 APEX study of PH-HFpEF, with topline data expected in 2026 and expansion into PH-ILD planned then also. TECX holds $268.4 million in cash, sufficient to fund operations into Q4 2028 and support multiple clinical milestones, including several catalysts.
Read More
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Tectonic Therapeutic, Inc. (TECX)
- IPO Date
- Website https://tectonictx.com
- Industry Biotechnology
- CEO Alise S. Reicin
- Employees 51